Literature DB >> 21604303

Binding to the open conformation of HIV-1 protease.

Katrina W Lexa1, Heather A Carlson.   

Abstract

A recent crystal structure of HIV-1 protease (HIVp) was the first to experimentally observe a ligand targeting an open-flap conformation. Researchers studying a symmetric pyrrolidine inhibitor found that two ligands cocrystallized with the protease, forcing an unusual configuration and unique crystallographic contacts. One molecule is centered in the traditional binding site (α pose) and the other binds between the flaps (β pose). The ligands stack against each other in a region termed the "eye" site. Ligands bound to the eye site should prevent flap closure, but it is unclear if the pyrrolidine inhibitors or the crystal packing are causing the open state. Molecular dynamics simulations were used to examine the solution-state behavior of three possible binding modes: the ternary complex of HIVp+αβ and the binary complexes, HIVp+α and HIVp+β. We show that HIVp+α is the most stable of the three states. During conformational sampling, α takes an asymmetric binding pose, with one naphthyl ring occupying the eye site and the other reoriented down to occupy positions seen with traditional inhibitors. This finding supports previous studies that reveal a requirement for asymmetric binding at the eye site. In fact, if the α pose is modified to splay both naphthyl rings across the binding site like traditional inhibitors, one ring consistently flips to occupy the eye site. Our simulations reveal that interactions to the eye site encourage a conformationally restrained state, and understanding those contacts may aid the design of ligands to specifically target alternate conformations of the protease.
Copyright © 2011 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21604303      PMCID: PMC3124008          DOI: 10.1002/prot.23054

Source DB:  PubMed          Journal:  Proteins        ISSN: 0887-3585


  22 in total

1.  Electrostatics of nanosystems: application to microtubules and the ribosome.

Authors:  N A Baker; D Sept; S Joseph; M J Holst; J A McCammon
Journal:  Proc Natl Acad Sci U S A       Date:  2001-08-21       Impact factor: 11.205

2.  Fast, efficient generation of high-quality atomic charges. AM1-BCC model: II. Parameterization and validation.

Authors:  Araz Jakalian; David B Jack; Christopher I Bayly
Journal:  J Comput Chem       Date:  2002-12       Impact factor: 3.376

3.  Development and testing of a general amber force field.

Authors:  Junmei Wang; Romain M Wolf; James W Caldwell; Peter A Kollman; David A Case
Journal:  J Comput Chem       Date:  2004-07-15       Impact factor: 3.376

4.  Clustering Molecular Dynamics Trajectories: 1. Characterizing the Performance of Different Clustering Algorithms.

Authors:  Jianyin Shao; Stephen W Tanner; Nephi Thompson; Thomas E Cheatham
Journal:  J Chem Theory Comput       Date:  2007-11       Impact factor: 6.006

5.  "Wide-open" 1.3 A structure of a multidrug-resistant HIV-1 protease as a drug target.

Authors:  Philip Martin; John F Vickrey; Gheorghe Proteasa; Yurytzy L Jimenez; Zdzislaw Wawrzak; Mark A Winters; Thomas C Merigan; Ladislau C Kovari
Journal:  Structure       Date:  2005-12       Impact factor: 5.006

6.  Comparison of multiple Amber force fields and development of improved protein backbone parameters.

Authors:  Viktor Hornak; Robert Abel; Asim Okur; Bentley Strockbine; Adrian Roitberg; Carlos Simmerling
Journal:  Proteins       Date:  2006-11-15

7.  Targeting the open-flap conformation of HIV-1 protease with pyrrolidine-based inhibitors.

Authors:  Jark Böttcher; Andreas Blum; Stefanie Dörr; Andreas Heine; Wibke E Diederich; Gerhard Klebe
Journal:  ChemMedChem       Date:  2008-09       Impact factor: 3.466

Review 8.  Twenty-six years of anti-HIV drug discovery: where do we stand and where do we go?

Authors:  Youcef Mehellou; Erik De Clercq
Journal:  J Med Chem       Date:  2010-01-28       Impact factor: 7.446

9.  Rapid structural fluctuations of the free HIV protease flaps in solution: relationship to crystal structures and comparison with predictions of dynamics calculations.

Authors:  Darón I Freedberg; Rieko Ishima; Jaison Jacob; Yun-Xing Wang; Irina Kustanovich; John M Louis; Dennis A Torchia
Journal:  Protein Sci       Date:  2002-02       Impact factor: 6.725

10.  MolProbity: all-atom contacts and structure validation for proteins and nucleic acids.

Authors:  Ian W Davis; Andrew Leaver-Fay; Vincent B Chen; Jeremy N Block; Gary J Kapral; Xueyi Wang; Laura W Murray; W Bryan Arendall; Jack Snoeyink; Jane S Richardson; David C Richardson
Journal:  Nucleic Acids Res       Date:  2007-04-22       Impact factor: 16.971

View more
  5 in total

Review 1.  Highly resistant HIV-1 proteases and strategies for their inhibition.

Authors:  Irene T Weber; Daniel W Kneller; Andres Wong-Sam
Journal:  Future Med Chem       Date:  2015       Impact factor: 3.808

2.  Enantioselective organo-SOMO cycloadditions: a catalytic approach to complex pyrrolidines from olefins and aldehydes.

Authors:  Nathan T Jui; Jeffrey A O Garber; Fernanda Gadini Finelli; David W C MacMillan
Journal:  J Am Chem Soc       Date:  2012-07-10       Impact factor: 15.419

3.  An anti-diabetic drug targets NEET (CISD) proteins through destabilization of their [2Fe-2S] clusters.

Authors:  Henri-Baptiste Marjault; Ola Karmi; Ke Zuo; Dorit Michaeli; Yael Eisenberg-Domovich; Giulia Rossetti; Benoit de Chassey; Jacky Vonderscher; Ioav Cabantchik; Paolo Carloni; Ron Mittler; Oded Livnah; Eric Meldrum; Rachel Nechushtai
Journal:  Commun Biol       Date:  2022-05-10

4.  Enantioselective thiourea-catalyzed intramolecular cope-type hydroamination.

Authors:  Adam R Brown; Christopher Uyeda; Carolyn A Brotherton; Eric N Jacobsen
Journal:  J Am Chem Soc       Date:  2013-04-24       Impact factor: 15.419

5.  Ritonavir and xk263 Binding-Unbinding with HIV-1 Protease: Pathways, Energy and Comparison.

Authors:  Jianan Sun; Mark Anthony V Raymundo; Chia-En A Chang
Journal:  Life (Basel)       Date:  2022-01-13
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.